- Home
- DBRG vs PTGX Comparison
DBRG vs PTGX Comparison
Compare DBRG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- PTGX
- Stock Information
- Founded
- DBRG 1991
- PTGX 2006
- Country
- DBRG United States
- PTGX United States
- Employees
- DBRG N/A
- PTGX N/A
- Industry
- DBRG Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- PTGX Health Care
- Exchange
- DBRG Nasdaq
- PTGX Nasdaq
- Market Cap
- DBRG 2.3B
- PTGX 2.7B
- IPO Year
- DBRG 2009
- PTGX 2016
- Fundamental
- Price
- DBRG $11.83
- PTGX $38.10
- Analyst Decision
- DBRG Strong Buy
- PTGX Strong Buy
- Analyst Count
- DBRG 8
- PTGX 8
- Target Price
- DBRG $16.75
- PTGX $54.63
- AVG Volume (30 Days)
- DBRG 2.3M
- PTGX 638.0K
- Earning Date
- DBRG 02-20-2025
- PTGX 02-25-2025
- Dividend Yield
- DBRG 0.34%
- PTGX N/A
- EPS Growth
- DBRG 1689.35
- PTGX N/A
- EPS
- DBRG 0.76
- PTGX 2.68
- Revenue
- DBRG $876,649,000.00
- PTGX $323,795,000.00
- Revenue This Year
- DBRG N/A
- PTGX $441.08
- Revenue Next Year
- DBRG N/A
- PTGX N/A
- P/E Ratio
- DBRG $15.41
- PTGX $14.23
- Revenue Growth
- DBRG 680.46
- PTGX 125.73
- 52 Week Low
- DBRG $10.25
- PTGX $24.21
- 52 Week High
- DBRG $20.99
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- DBRG 56.78
- PTGX 46.07
- Support Level
- DBRG $10.60
- PTGX $35.03
- Resistance Level
- DBRG $11.68
- PTGX $40.07
- Average True Range (ATR)
- DBRG 0.46
- PTGX 1.57
- MACD
- DBRG 0.15
- PTGX 0.07
- Stochastic Oscillator
- DBRG 98.14
- PTGX 59.84
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.